PHILADELPHIA, April 13, 2020: Morgan Lewis represented Idera Pharmaceuticals Inc., a Pennsylvania-based clinical-stage biopharmaceutical company, in an agreement with a fund affiliated with an institutional investor providing for a private placement.
Idera’s lead development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development, and ultimate commercialization of drug candidates for both oncology and rare-disease indications.
Partners Joanne Soslow, Richard Aldridge, and David Schwartz, senior attorney Sally Liao, and associates Richard Umbrecht and Brittany Leon represented Idera.